THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT
A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood conc...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Bishop, Charles W Crawford, Keith H Petkovich, P. Martin Messner, Eric J Helvig, Christian F |
| description | A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3357496A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3357496A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3357496A13</originalsourceid><addsrcrecordid>eNrjZPAP8XANcgyIVAgN9vRzVwjzDHH09fRTcFEIcg3wcQ3x9PdTcHR39QtRcPRzQZL18A_y9fdzBatydHb1BasAqeNhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAcbGpuYmlmaOhsZEKAEA3h0uTg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT</title><source>esp@cenet</source><creator>Bishop, Charles W ; Crawford, Keith H ; Petkovich, P. Martin ; Messner, Eric J ; Helvig, Christian F</creator><creatorcontrib>Bishop, Charles W ; Crawford, Keith H ; Petkovich, P. Martin ; Messner, Eric J ; Helvig, Christian F</creatorcontrib><description>A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180808&DB=EPODOC&CC=EP&NR=3357496A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180808&DB=EPODOC&CC=EP&NR=3357496A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Bishop, Charles W</creatorcontrib><creatorcontrib>Crawford, Keith H</creatorcontrib><creatorcontrib>Petkovich, P. Martin</creatorcontrib><creatorcontrib>Messner, Eric J</creatorcontrib><creatorcontrib>Helvig, Christian F</creatorcontrib><title>THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT</title><description>A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAP8XANcgyIVAgN9vRzVwjzDHH09fRTcFEIcg3wcQ3x9PdTcHR39QtRcPRzQZL18A_y9fdzBatydHb1BasAqeNhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAcbGpuYmlmaOhsZEKAEA3h0uTg</recordid><startdate>20180808</startdate><enddate>20180808</enddate><creator>Bishop, Charles W</creator><creator>Crawford, Keith H</creator><creator>Petkovich, P. Martin</creator><creator>Messner, Eric J</creator><creator>Helvig, Christian F</creator><scope>EVB</scope></search><sort><creationdate>20180808</creationdate><title>THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT</title><author>Bishop, Charles W ; Crawford, Keith H ; Petkovich, P. Martin ; Messner, Eric J ; Helvig, Christian F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3357496A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Bishop, Charles W</creatorcontrib><creatorcontrib>Crawford, Keith H</creatorcontrib><creatorcontrib>Petkovich, P. Martin</creatorcontrib><creatorcontrib>Messner, Eric J</creatorcontrib><creatorcontrib>Helvig, Christian F</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bishop, Charles W</au><au>Crawford, Keith H</au><au>Petkovich, P. Martin</au><au>Messner, Eric J</au><au>Helvig, Christian F</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT</title><date>2018-08-08</date><risdate>2018</risdate><abstract>A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3357496A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | THERAPY USING VITAMIN D REPLETION AGENT AND VITAMIN D HORMONE REPLACEMENT AGENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A13%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Bishop,%20Charles%20W&rft.date=2018-08-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3357496A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |